Search the Newsreel

West Pharmaceutical Services Inc. stock underperforms Friday when compared to competitors

West Pharmaceutical Services Inc. (WST) stock fell 7.67% on Friday, closing at $328.20. This underperformance occurred despite a positive trading session for the broader market, with the S&P 500 rising 0.05% and the Dow Jones Industrial Average rising 0.46%. This marks the stock's third …

Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know

Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics experienced stock declines following concerns about a rising number of uninsured patients, as highlighted in HCA Healthcare's recent earnings report. HCA reported a "negative payer mix shift" leading to a $400 million reduction …

WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook

WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 13.8% year on year to $872.3 million. Guidance for next quarter's revenue was …

Sei Investments Co. Has $132.65 Million Stake in West Pharmaceutical Services, Inc. $WST

Sei Investments Co. has a significant stake worth $132.65 million in West Pharmaceutical Services, Inc., despite trimming its holdings by 10.6% in the first quarter. The medical instruments supplier has shown strong financial performance, beating Q2 expectations with EPS of $2.37 and revenue of …

West Pharmaceutical Earnings: Another Strong Quarter and Upward Guidance Revision

West Pharmaceutical's Long-Term Growth Intact

This article from Morningstar reaffirms West Pharmaceutical's long-term growth prospects, highlighting its leadership in primary packaging and delivery components for injectable therapeutics. The company benefits from the critical nature of its products which require strict regulatory standards, supporting continued trust from customers. Key product …

West Pharmaceutical Services Inc 2Q 2026: Revenue $872.3M, EPS $2.15— 10-Q Summary

West Pharmaceutical Services Inc. (WST) reported strong results for the second quarter of 2026, with revenue reaching $872.3M and diluted EPS at $2.15, driven by high demand for proprietary products. The company saw growth in HVP components and devices, including those for biologics and …

West Pharma says sterile packaging upgrades fuel demand for high-value plastics

West Pharmaceutical Services indicates that new European Union regulations regarding materials and sterile packaging are increasing the demand for high-value plastics. This surge in interest is particularly noted in the pharmaceutical packaging sector. The article highlights how these regulatory changes are influencing material choices …

West Pharma raises profit forecast on strong demand for injectable drug components

West Pharmaceutical Services has raised its annual profit forecast, driven by robust demand for its components used in injectable drugs. The company reported strong Q2 adjusted earnings and net sales, exceeding analyst estimates. These positive results prompted West Pharma to boost its full-year 2026 …

West Pharmaceutical (WST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2026, West Pharmaceutical Services (WST) reported revenue of $872.3 million, up 13.8% over the same period last year. EPS came in at $2.37, compared to $1.84 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate …

Earnings call transcript: West Pharmaceutical beats Q2 2026 estimates, lifts outlook

West Pharmaceutical Services (WST) reported stronger-than-expected Q2 2026 results, with adjusted EPS up 29% to $2.37 and revenue climbing 13.8% to $872.3 million, both beating analyst estimates. The company raised its full-year guidance for sales and profit, driven by strong demand in biologics, GLP-1 …

Why is West Pharmaceutical Services stock surging today?

West Pharmaceutical Services Inc. stock surged 6.1% in pre-open trading after reporting second-quarter 2026 results that significantly beat Wall Street expectations for both earnings and revenue. The company also raised its full-year 2026 adjusted EPS guidance, signaling strong momentum in high-value injectable drug

West Pharmaceutical Services Releases Q2 2026 Financial Results

West Pharmaceutical Services (WST) reported strong Q2 2026 financial results, with adjusted EPS of $2.37, beating estimates by 13.9%, and revenue of $872.3 million, exceeding expectations by 3.8%. The company saw significant growth in its Proprietary Products segment and maintains a positive outlook for …

West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars

West Pharmaceutical Services (NYSE:WST) reported strong Q2 CY2026 results, exceeding revenue and adjusted EPS expectations. The company saw a 13.8% year-on-year revenue increase to $872.3 million and an adjusted EPS of $2.37, beating analyst estimates by 13.9%. Following the positive report, the company also …

Form 8-K WEST PHARMACEUTICAL SERV For: Jul 23

West Pharmaceutical Services, Inc. filed a Form 8-K on July 23, 2026, to announce its second-quarter 2026 financial results. The report includes a press release (Exhibit 99.1) and presentation materials (Exhibit 99.2) related to these results. The company also confirmed its registration with the …

West Pharmaceutical Services (WST) Q2 Earnings and Revenues Top Estimates

West Pharmaceutical Services (WST) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.08 per share. This compares to earnings of $1.84 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents …

West Pharmaceutical Services Q2 Adjusted Earnings, Net Sales Rise; 2026 Outlook Boosted

West Pharmaceutical Services (WST) reported Q2 adjusted earnings Thursday of $2.37 per diluted share PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

West Pharmaceutical Services Inc. Bottom Line Rises In Q2

(RTTNews) - West Pharmaceutical Services Inc. (WST) revealed a profit for its second quarter that Increases, from last year The company's bottom line totaled $154.0 million, or $2.15 per share. This compares with $131.8 million, or $1.82 per share, last year. Excluding items, West …

Earnings Flash (WST) West Pharmaceutical Services, Inc. Posts Q2 Adjusted EPS $2.37 per Share, Vs. FactSet Est of $2.08

West Pharmaceutical Services, Inc. (WST) reported strong Q2 adjusted earnings per share of $2.37, significantly exceeding FactSet's estimate of $2.08. This financial update highlights the company's performance relative to analyst expectations.

West Reports Second-Quarter 2026 Results

West Pharmaceutical Services, Inc. announced strong financial results for the second quarter of 2026, with net sales increasing by 13.8% to $872.3 million and adjusted-diluted EPS rising by 28.8% to $2.37. The company raised its full-year 2026 guidance for both net sales and adjusted-diluted …

WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth

West Pharmaceutical Services, Inc. WST delivered adjusted second-quarter 2026 earnings per share (EPS) of $2.37, which moved up 28.8% year over year. The figure topped the Zacks Consensus Estimate by 13.9%. The adjustments include expenses related to the amortization of acquisition-related intangible assets, among …

West Pharmaceutical: Q2 Earnings Snapshot

West Pharmaceutical Services Inc. (WST) reported second-quarter profit of $154 million, or $2.15 per share, surpassing Wall Street expectations with adjusted earnings of $2.37 per share. The medical device company also exceeded revenue forecasts, posting $872.3 million. The company provided optimistic guidance for the …

West Pharma stock rises nearly 33% YTD on strong Q2 outlook and growing demand for biologics components.

West Pharmaceutical Services (WST) has seen its stock rise nearly 33% year-to-date, driven by a positive Q2 outlook and increasing demand for components used in biologics and GLP-1 drugs. Analysts are bullish on the company, expecting an earnings beat and continued growth through 2026 …

West Pharmaceutical Services, Inc. (WST) Q3 2025 Earnings Report - Results, Call & Slides

West Pharmaceutical Services (WST) reported strong Q3 2025 earnings, beating analyst expectations for both EPS and revenue. The company posted an actual EPS of $1.96 against a consensus of $1.69, and actual revenue of $804.30 million exceeding the expected $785.71 million. WST also announced …

West Pharmaceutical Services (WST) Q2 Earnings Report Preview: What To Look For

West Pharmaceutical Services (WST) is expected to announce its Q2 earnings tomorrow, with analysts anticipating a 9.9% year-on-year revenue growth. The company has a strong record of beating revenue estimates and exceeded both revenue and EPS expectations last quarter. West Pharmaceutical Services is the …

West (WST) Stock Looks Pricey With Little Room Above Fair Value

West Pharmaceutical Services (WST) stock has seen a significant 64.7% return over the past year, but current valuations suggest it may be overvalued. While its Discounted Cash Flow (DCF) estimate indicates the stock is trading close to its intrinsic value, its high P/E ratio …

West Pharmaceutical Services declares $0.22 quarterly dividend By Investing.com

West Pharmaceutical Services, Inc. announced that its Board of Directors declared a regular quarterly dividend of $0.22 per share on the company’s common stock. The dividend is payable on August 5, 2026, to shareholders of record as of July 29, 2026. West Pharmaceutical Services …

West Sets July 29 Record Date for $0.22 Dividend Payment

West Pharmaceutical Services (NYSE: WST) announced that its Board of Directors declared a regular quarterly dividend of $0.22 per share on its common stock. The dividend will be paid on August 5, 2026, to shareholders of record as of July 29, 2026. The company, …

West Pharmaceutical Services (WST) On Daikyo Deal Looks Closer To Fully Valued

West Pharmaceutical Services (WST) has established two long-term distributorship agreements with Daikyo Seiko, allowing mutual distribution rights for their products in different regions. Although the stock has seen significant short-term gains, its current price of $352.32 is near analyst targets, suggesting that the positive …

Curious about West Pharmaceutical (WST) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Wall Street analysts forecast that West Pharmaceutical Services (WST) will report quarterly earnings of $2.08 per share in its upcoming release, pointing to a year-over-year increase of 13%. It is anticipated that revenues will amount to $836.8 million, exhibiting an increase of 9.2% compared …

West Pharmaceutical Services Inc. stock underperforms Monday when compared to competitors

Shares of West Pharmaceutical Services Inc. (WST) fell by 1.65% to $352.32 on Monday, underperforming the broader market. This decline occurred during a generally negative trading session, with the S&P 500 Index and Dow Jones Industrial Average also experiencing losses. This marks the second …

MMSI vs. WST: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Merit Medical (MMSI) or West Pharmaceutical Services (WST). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to …

Stephens Adjusts West Pharmaceutical Services Price Target to $410 From $360, Maintains Overweight Rating

Stephens has increased its price target for West Pharmaceutical Services (WST) to $410 from $360, while reiterating an Overweight rating on the stock. This adjustment reflects analysts' continued positive outlook on the medical equipment and supplies company. Other analysts from firms like TD Cowen …

West Pharmaceutical Services (WST) Q2 2026 Preview: EPS Est. $2.08, Reports July 23

West Pharmaceutical Services (NYSE:WST) is set to report its Q2 2026 earnings on July 23, with analysts projecting an EPS of $2.08 and revenue of $840.0M. The company has a strong track record, consistently beating analyst expectations in the past four quarters, driven by …

Should West’s 10-Year Global Daikyo Distribution Pact Reshape the GLP-1 Narrative for WST Investors?

West Pharmaceutical Services has entered into two 10-year distributorship agreements with Daikyo Seiko, granting West exclusive distribution rights for Daikyo products outside Japan and Daikyo non-exclusive rights for West products within Japan. This partnership deepens West's involvement in high-value injectable components, particularly for GLP-1 …

West (WST) Stock Looks Fair On Cash Flow Yet Pricey On Earnings

West Pharmaceutical Services (WST) has seen a 64.1% return in the past year, leading to a premium valuation. While a Discounted Cash Flow (DCF) analysis suggests the stock is roughly fair, its P/E ratio of 47.2x indicates it's expensive compared to industry averages and …